CPC C07C 69/734 (2013.01) [A61K 9/7023 (2013.01); C07C 53/136 (2013.01); C07C 59/11 (2013.01); C07C 59/13 (2013.01); C07C 69/28 (2013.01); C07C 69/675 (2013.01); C07C 69/68 (2013.01); C07C 69/708 (2013.01); C07C 69/712 (2013.01); C07C 69/74 (2013.01); C07C 69/75 (2013.01); C07C 69/96 (2013.01); C07D 305/08 (2013.01); C07D 307/24 (2013.01); C07D 307/30 (2013.01); C07D 309/08 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2603/14 (2017.05)] | 13 Claims |
1. A method of promoting vasodilation, inhibiting platelet activation or aggregation, inhibiting thrombus formation, stimulating thrombolysis, inhibiting atherogenesis, inhibiting cell proliferation, promoting endothelial cell membrane remodeling, reducing inflammation, or providing cytoprotection, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of Formula (II):
wherein:
O—Z—CO2H is
—O-heteroalkyl-CO2H, —O-cyclyl-CO2H, —O—CH2-cyclyl-CO2H, —O-cyclyl-CH2—CO2H, or —O—CH2-cyclyl-CH2—CO2H, each of which may optionally be substituted, wherein:
cyclyl- is -cycloalkyl-, -heterocyclyl-, -aryl- or -heteroaryl-;
R7 and R8 in each occurrence independently are hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl, or R7 and R8 and the carbon atom to which they are connected form a C3-C6 cycloalkyl ring; and
n is an integer from 1 to 10;
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof, with the proviso that:
—O—Z—CO2H is not
and
—O—Z—CO2H does not contain a sugar moiety.
|